Business Description
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Business History
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 9.72
Total Equity: -$651.08M
Shares: 88,100,000
Total Debt: $12.45B
Cash: $757.75M
EBITDA: $2.64B
Total Debt: $12.45B
Cash: $757.75M
Revenue: $13.64B
Revenue: $13.64B
Revenue: $13.64B
Total Equity: -$651.08M
Tax Rate: 21.8%
Equity: -$651.08M
Total Debt: $12.45B
Cash: $757.75M
Current Liabilities: $3.14B
Long-Term Debt: $12.34B
Total Debt: $12.45B
Total Equity: -$651.08M
Shares: 88,100,000
Shares: 88,100,000
CapEx: -$575.86M
Shares: 88,100,000
Stock Price: $214.82
Net Income: $746.80M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 25, 2026 3:22am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $11.6B | $11.6B | $12.1B | $12.8B | $13.6B |
| Cost of Revenue | $8.0B | $8.2B | $8.3B | $8.6B | $10.0B |
| Gross Profit | $3.6B | $3.4B | $3.8B | $4.2B | $3.7B |
| Operating Expenses | $1.8B | $2.1B | $2.2B | $2.1B | $1.7B |
| Operating Income | $1.8B | $1.3B | $1.6B | $2.1B | $2.0B |
| Net Income | $978.5M | $560.4M | $691.5M | $936.3M | $746.8M |
| EBITDA | $2.5B | $2.1B | $2.3B | $2.7B | $2.6B |
| EPS | $9.30 | $5.88 | $7.62 | $11.02 | $9.72 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 25, 2026 3:22am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $461.9M | $244.1M | $380.1M | $794.9M | $757.7M |
| Total Current Assets | $3.2B | $3.2B | $3.1B | $3.7B | $4.1B |
| Total Assets | $17.1B | $16.9B | $16.9B | $17.3B | $17.5B |
| Current Liabilities | $2.4B | $2.6B | $2.6B | $3.0B | $3.1B |
| Long-Term Debt | $8.7B | $8.7B | $8.3B | $9.2B | $12.3B |
| Total Liabilities | $14.8B | $14.7B | $14.2B | $15.2B | $16.3B |
| Total Equity | $755.5M | $712.3M | $1.1B | $121.1M | -$651.1M |
| Retained Earnings | $354.3M | $174.5M | $598.3M | $1.5B | -$328.4M |
Cash Flow (Annual)
Last updated: Jun 25, 2026 3:22am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.9B | $1.6B | $2.1B | $2.0B | $1.9B |
| Capital Expenditure | -$641.5M | -$603.4M | -$568.0M | -$555.4M | -$575.9M |
| Free Cash Flow | $1.3B | $961.1M | $1.5B | $1.5B | $1.3B |
| Acquisitions (net) | -$201.0M | -$89.2M | -$26.4M | -$251.3M | -$144.5M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$1.6B | -$802.2M | -$272.2M | -$1.4B | -$1.8B |
| Net Change in Cash | $53.2M | -$216.0M | $125.6M | $415.2M | -$122.1M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 11:58am (22h ago)| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$14.1B $13.9B – $14.3B
|
$14.5B $14.3B – $14.9B
|
$14.6B $14.3B – $14.9B
|
$15.9B $15.6B – $16.3B
|
| EBITDA |
$2.8B $2.8B – $2.8B
|
$2.9B $2.8B – $3.0B
|
$2.9B $2.8B – $2.9B
|
$3.1B $3.1B – $3.2B
|
| Net Income |
$1.3B $1.3B – $1.4B
|
$1.5B $1.4B – $1.6B
|
$1.7B $1.6B – $1.7B
|
$1.6B $1.6B – $1.7B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 25, 2026 3:22am (2d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -0.1% | +4.6% | +5.6% | +6.5% |
| Gross Profit Growth | -6.7% | +12.4% | +10.4% | -12.6% |
| Operating Income Growth | -25.5% | +19.7% | +30.4% | -3.8% |
| Net Income Growth | -42.7% | +23.4% | +35.4% | -20.2% |
| EBITDA Growth | -17.2% | +12.9% | +17.4% | -3.0% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 9:06am (1h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-15 | Waters Kathleen Alyce | S-Sale | 8,950.00 | $207.84 | $1.9M |
| 2026-06-15 | Waters Kathleen Alyce | S-Sale | 6,455.00 | $209.17 | $1.4M |
| 2026-06-15 | Rodriguez Javier | S-Sale | 30,000.00 | $209.50 | $6.3M |
| 2026-06-16 | Rodriguez Javier | S-Sale | 39,407.00 | $209.28 | $8.2M |
| 2026-05-26 | YALE PHYLLIS R | G-Gift | 5,038.00 | $0.00 | $0 |
| 2026-05-15 | Pullin Dennis W | A-Award | 250.00 | $0.00 | $0 |
| 2026-05-15 | Moore Gregory J. | A-Award | 250.00 | $0.00 | $0 |
| 2026-05-15 | Schoppert Wendy Lee | A-Award | 250.00 | $0.00 | $0 |
| 2026-05-15 | Arway Pamela M | A-Award | 250.00 | $0.00 | $0 |
| 2026-05-15 | YALE PHYLLIS R | A-Award | 250.00 | $0.00 | $0 |
| 2026-05-15 | DESOER BARBARA J | A-Award | 250.00 | $0.00 | $0 |
| 2026-05-15 | Schechter Adam H | A-Award | 250.00 | $0.00 | $0 |
| 2026-05-15 | Hollar Jason M. | A-Award | 250.00 | $0.00 | $0 |
| 2026-05-14 | HEARTY JAMES O | M-Exempt | 5,784.00 | $110.63 | $639,884 |
| 2026-05-14 | HEARTY JAMES O | D-Return | 3,231.00 | $198.10 | $640,061 |
| 2026-05-14 | HEARTY JAMES O | F-InKind | 1,117.00 | $198.10 | $221,278 |
| 2026-05-15 | HEARTY JAMES O | S-Sale | 15,000.00 | $193.98 | $2.9M |
| 2026-05-14 | HEARTY JAMES O | M-Exempt | 5,784.00 | $110.63 | $639,884 |
| 2026-05-11 | Maughan David Paul | S-Sale | 7,073.00 | $199.15 | $1.4M |
| 2026-05-12 | Maughan David Paul | S-Sale | 13,456.00 | $199.25 | $2.7M |
Narrative Economics
market-narrative step).